Intellia touts first clinical outcomes on CRISPR-based ATTR amyloidosis assetnews2024-11-18T09:09:43+00:00November 18th, 2024|Endpoints News|
Scottish biotech Trogenix debuts with viral immunotherapy platform for cancernews2024-11-18T07:00:06+00:00November 18th, 2024|Endpoints News|
Eisai terminates Phase 3 trial of Dravet drug lorcaserinnews2024-11-17T10:27:08+00:00November 17th, 2024|Endpoints News|
Trump picks RFK Jr. for HHS; AbbVie’s psych implosion; Merck tries staving off Summit; and morenews2024-11-16T11:00:06+00:00November 16th, 2024|Endpoints News|
Illumina seeks to dismiss shareholder lawsuit, denies secret $800M stakenews2024-11-15T19:18:46+00:00November 15th, 2024|Endpoints News|
What is the future of the Trump administration’s pharmaceutical policies?news2024-11-15T19:08:08+00:00November 15th, 2024|Endpoints News|
European drug regulators offer wave of positive recommendations following Leqembi reversalnews2024-11-15T17:44:05+00:00November 15th, 2024|Endpoints News|
Eyenovia’s stock falls after it halts late-stage myopia trialnews2024-11-15T16:01:01+00:00November 15th, 2024|Endpoints News|
Boston Pharmaceuticals’ Phase 2 MASH trial hits efficacy endpointsnews2024-11-15T16:00:21+00:00November 15th, 2024|Endpoints News|
Vitalli ends work on Daewoong asset; Alector’s $50M loannews2024-11-15T15:35:35+00:00November 15th, 2024|Endpoints News|
